Application of Rhuepo to Post-Chemotherapy Blood Cancer Patients and Clinical Observation

Aim: Clinical use of Recombinant Human Erythropoietin (rHuEPO) effectively increases the level of Hemoglobin in blood and improve quality of life of patients. Methods: Blood cancer patients is divided into two groups namely Treatment group and Control group. There is altogether 24 patients in treatment gp to whom both chemotherapy and rHuEPO is given for 4 weeks. rHuEPO is given as 150u/kg，subcutaneously, three times a week. Blood routine check up is done in every week and iron is prescribed after 2 weeks. Result: After 4 weeks of treatment, patients were evaluated for drugs effectiveness in both groups; total effectiveness were 58.34% and 20% respectively, P >0.05; after 4 weeks of treatment, there was distinct statistical significance. Comparing with pretreatment level, Treatment group has remarkable rise in Hb after 4 weeks (81.29±9.85)对（65.75±12.37），（P<0.01, whereas control group has not distinct change in Hb level(86.95±11.61)对（84.30±16.25），（P>0.05. Conclusion: Hb is significantly increased after the use of rHuEPO and side effects were less with well tolerances.